Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis

Analysis of Efficiency and Tolerance of Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis Occuring During First-line BRAFinh/MEKinh Therapy.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05510466

Enrollment

Registered

2022-08-22

Start date

2019-01-01

Completion date

2023-03-01

Last updated

2022-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Melanoma

Keywords

Initially treated by a doubled targeted therapy anti BRAF/anti MEK, immunotherapy, combined tritherapy, melanoma's brain metastasis, With an intra cerebral progression of the tumor

Brief summary

Currently, therapeutic options in BRAF mutated melanoma with brain metastasis occurring after achievement of a good control of extracerebral secondary lesions by a first line combined targeted therapy (TT) are limited. In this setting, the addition of an anti PD1 agent to TT may be proposed as a second line strategy. This observational survey aims at investigating the benefit/risk ratio of this triple combination in a small cohort of patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Metastatic melanoma BRAF mutated * Initially treated by a doubled targeted therapy anti BRAF/anti MEK * With an intra cerebral progression of the tumor * Whom we add an check point inhibitor anti PD1, combined with the double targeted therapy * between 01/2019 et 01/2022

Exclusion criteria

\- Other condition

Design outcomes

Primary

Measure	Time frame	Description
comparison between intra and extra cerebral metastasis	day 1	comparison between intra and extra cerebral metastasis

Countries

France

Contacts

Primary ContactOlivier DEREURE, MD, PhD

o-dereure@chu-montpellier.fr467336906

Backup ContactMarie Louise Jeanne, resident

Outcome results